Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Sep;36(5):315–322. doi: 10.1007/BF01741170

Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2

Flavio Arienti 1,✉, Filiberto Belli 2, Licia Rivoltini 1, Carlo Gambacorti-Passerini 1, Luigi Furlan 2, Luigi Mascheroni 2, Augusto Prada 3, Maurilia Rizzi 3, Edoardo Marchesi 1, Maurizio Vaglini 2, Giorgio Parmiani 1, Natale Cascinelli 2
PMCID: PMC11038306  PMID: 8477417

Abstract

Freshly isolated tumor-infiltrating lymphocytes (TIL) from stage IV melanoma patients were cultured for 2 weeks with low doses of interleukin-2 (IL-2; 120 IU/ml), to select potentially for tumor-specific lymphocytes present in the neoplastic lesion, followed by high doses (6000 IU/ml) to achieve lymphocyte expansion. TIL were serially analyzed for their expansion, phenotype and cytotoxic activity against autologous and allogeneic tumor cells. A preferential lysis of autologous melanoma cells was obtained in long-term cultures of 7/13 cases (54%), while the remaining ones showed a major-histocompatibility-complex-unrestricted, lymphokine-activated-killer(LAK)-like activity at the time of in vivo injection. Sixteen patients with metastatic melanoma were infused with TIL (mean number: 6.8×109, range: 0.35 × 109−20 × 109) and IL-2 (mean dose: 130 × 106 IU, range: 28.8 × 106−231 × 106 IU); 1 complete and 3 partial responses were observed in 12 evaluable patients (response rate 33%). In all responding patients, injected TIL showed an in vitro preferential lysis of autologous tumor cells, while in no cases were TIL with LAK-like activity associated with a clinical response. The mean autologous tumor cytotoxic activity of TIL at the time of in vivo injection was significantly higher in responding patients in comparison to nonresponding ones, suggesting that a marked and preferential cytolysis of autologous tumor cells is associated with the therapeutic efficacy of TIL.

Key words: Melanoma, Interleukin-2, Tumor-infiltrating lymphocytes, Immunotherapy

References

  • 1.Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. JNCI. 1991;83:932–932. doi: 10.1093/jnci/83.13.932. [DOI] [PubMed] [Google Scholar]
  • 2.Anichini A, Mazzocchi A, Fossati G, Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor side detect intratumor heterogeneity of melanoma cells. J Immunol. 1989;142:3692–3692. [PubMed] [Google Scholar]
  • 3.Blankenstein T, Rowley DA, Schreiber H. Cytokines and cancer: experimental systems. Curr Op Immunol. 1991;3:694–694. doi: 10.1016/0952-7915(91)90098-l. [DOI] [PubMed] [Google Scholar]
  • 4.Cascinelli N, Belli F, Marchini S, Marolda R, Prada A, Sciorelli G, Villani F, Gambacorti-Passerini C, Galazka A, Parmiani G. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients. Tumori. 1989;75:233–233. doi: 10.1177/030089168907500309. [DOI] [PubMed] [Google Scholar]
  • 5.Cascinelli N, Belli F, Santinami M, Vaglini M. Chemoimmunotherapy of cutaneous melanoma. In: Dammacco F, editor. Frontiers in autoimmune diseases and cancer immunotherapy. Milan: Edi-ermes; 1992. pp. 273–273. [Google Scholar]
  • 6.Crowley NJ, Slingluff CL, Darrow TL, Seigler HF. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res. 1990;50:492–492. [PubMed] [Google Scholar]
  • 7.Darrow TL, Slingluff CL, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. J Immunol. 1989;142:3329–3329. [PubMed] [Google Scholar]
  • 8.Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, Yannelli JR, Maleckar JR, Sferruzza A, Arnold J, West WH. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. Cancer. 1991;68:1–1. doi: 10.1002/1097-0142(19910701)68:1<1::aid-cncr2820680102>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  • 9.Giacomini P, Fraioli R, Calabro' AM, Di Filippo F, Natali PG. Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Res. 1991;51:652–652. [PubMed] [Google Scholar]
  • 10.Hoogstraten B. Reporting treatment results in solid tumor. In: Buyse ME, Staquet MJ, Sylvester RJ, editors. Cancer clinical trials, methods and pratice. Oxford: Oxford University Press; 1988. pp. 139–139. [Google Scholar]
  • 11.Kradin RL, Lazarus DS, Dubinett SM, Gifford J, Grove B, Kurnick JT, Preffer FI, Pinto CE, Davidson E, Callahan RJ, Strauss HW. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989;I:577–577. doi: 10.1016/s0140-6736(89)91609-7. [DOI] [PubMed] [Google Scholar]
  • 12.Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, Parkinson DR, Wiernik PH, Creekmore SP, Boldt DH. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumor: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7:486–486. doi: 10.1200/JCO.1989.7.4.486. [DOI] [PubMed] [Google Scholar]
  • 13.Mastrangelo MJ, Berd D, Maguire H. The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol. 1986;13:186–186. [PubMed] [Google Scholar]
  • 14.Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol. 1992;10:1158–1158. doi: 10.1200/JCO.1992.10.7.1158. [DOI] [PubMed] [Google Scholar]
  • 15.Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA. 1989;86:6719–6719. doi: 10.1073/pnas.86.17.6719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Parmiani G, Anichini A, Carbone G, Sensi ML. Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy? Melanoma Res. 1992;2:123–123. doi: 10.1097/00008390-199207000-00007. [DOI] [PubMed] [Google Scholar]
  • 17.Radrizzani M, Gambacorti-Passerini C, Parmiani G, Fossati G. Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells. Cancer Immunol Immunother. 1989;28:67–67. doi: 10.1007/BF00205803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother. 1992;34:241–241. doi: 10.1007/BF01741792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol. 1992;10:180–180. doi: 10.1200/JCO.1992.10.2.180. [DOI] [PubMed] [Google Scholar]
  • 20.Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676–1676. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  • 21.Rosenberg SA, Schwarz SL, Spiess PJ. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alpha-interferon, and tumor-infiltrating lymphocytes. JNCI. 1988;80:1393–1393. doi: 10.1093/jnci/80.17.1393. [DOI] [PubMed] [Google Scholar]
  • 22.Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B. Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res. 1988;48:2561–2561. [PubMed] [Google Scholar]
  • 23.Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2. A pilot study. J Clin Oncol. 1988;6:839–839. doi: 10.1200/JCO.1988.6.5.839. [DOI] [PubMed] [Google Scholar]
  • 24.Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989;142:3714–3714. [PubMed] [Google Scholar]
  • 25.van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1643. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]
  • 26.Vanky F, Wang P, Patarroyo M, Klein E. Expression of the adhesion molecule ICAM1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother. 1990;31:19–19. doi: 10.1007/BF01742491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Weber JS, Rosenberg SA. Effect of murine tumor class I major histocompatibility complex expression on anti-tumor activity of tumor-infiltrating lymphocytes. JNCI. 1990;82:755–755. doi: 10.1093/jnci/82.9.755. [DOI] [PubMed] [Google Scholar]
  • 28.Yang JC, Perry-Lalley D, Rosenberg SA. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Mod. 1990;9:149–149. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES